Tate B F, Allenby G, Janocha R, Kazmer S, Speck J, Sturzenbecker L J, Abarzúa P, Levin A A, Grippo J F
Department of Toxicology, Hoffmann-La Roche Inc., Nutley, New Jersey 07110.
Mol Cell Biol. 1994 Apr;14(4):2323-30. doi: 10.1128/mcb.14.4.2323-2330.1994.
Retinoids exert their physiological action by interacting with two families of nuclear receptors, the retinoic acid receptors (RARs) and the retinoid X receptors (RXRs), which regulate gene expression by forming transcriptionally active heterodimeric RAR/RXR or homodimeric RXR/RXR complexes on DNA. Retinoid receptor activity resides in several regions, including the DNA and ligand binding domains, a dimerization interface, and both a ligand-independent (AF-1) and a ligand-dependent (AF-2) transactivation function. While 9-cis retinoic acid (RA) alone is the cognate ligand for the RXRs, both 9-cis RA and all-trans RA (t-RA) compete for binding with high affinity to the RARs. This latter observation suggested to us that the two isomers may interact with a common binding site. Here we report that RAR alpha has two distinct but overlapping binding sites for 9-cis RA and t-RA. Truncation of a human RAR alpha to 419 amino acids yields a receptor that binds both t-RA and 9-cis RA with high affinity, but truncation to amino acid 404 yields a mutant receptor that binds only t-RA with high affinity. Remarkably, this region also defines a C-terminal boundary for AF-2, as addition of amino acids 405 to 419 restores receptor-mediated gene activity to a truncated human RAR alpha lacking this region. It is interesting to speculate that binding of retinoid stereoisomers to unique sites within an RAR may function with AF-2 to cause differential activation of retinoid-responsive gene pathways.
维甲酸通过与两类核受体相互作用发挥其生理作用,这两类核受体分别是维甲酸受体(RARs)和维甲酸X受体(RXRs),它们通过在DNA上形成具有转录活性的异源二聚体RAR/RXR或同源二聚体RXR/RXR复合物来调节基因表达。维甲酸受体活性存在于几个区域,包括DNA和配体结合结构域、二聚化界面以及一个不依赖配体的(AF-1)和一个依赖配体的(AF-2)反式激活功能区。虽然单独的9-顺式维甲酸(RA)是RXRs的同源配体,但9-顺式RA和全反式RA(t-RA)都能以高亲和力竞争与RARs的结合。后一观察结果向我们表明,这两种异构体可能与一个共同的结合位点相互作用。在此我们报告,RARα对9-顺式RA和t-RA有两个不同但重叠的结合位点。将人RARα截短至419个氨基酸产生一种受体,它能以高亲和力结合t-RA和9-顺式RA,但截短至404个氨基酸产生一种突变受体,它只能以高亲和力结合t-RA。值得注意的是,该区域还定义了AF-2的C末端边界,因为添加405至419位氨基酸可将受体介导的基因活性恢复到缺乏该区域的截短型人RARα。有趣的是,可以推测维甲酸立体异构体与RAR内独特位点的结合可能与AF-2共同作用,导致维甲酸反应性基因途径的差异激活。